Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361047 | 1.00 | ADRB2 (0.39) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL35668 | 0.91 | ADRB2 (0.45) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL6448719 | 0.88 | ADRB2 (0.43) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL31482751 | 0.88 | ADRB2 (0.43) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL1538446 | 0.88 | ADRB2 (0.43) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL9147120 | 0.86 | ADRB2 (0.41) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL9149058 | 0.86 | ADRB2 (0.41) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL9147450 | 0.86 | ADRB2 (0.41) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| Lithium Ion SCHEMBL10405172 | 0.83 | ADRB2 (0.39) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL11394915 | 0.83 | THRB (0.44) | TSHRCA1CA2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3034547-B1 | A process for the preparation of a block copolymer comprising a first polyolefin block and a second polymer block | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2019-10-09 | — | — | EP | claimed |
| EP-3034547-A1 | A process for the preparation of a block copolymer comprising a first polyolefin block and a second polymer block and the products obtained therefrom | SABIC Global Technologies B.V. (NL) | 2016-06-22 | — | — | EP | claimed |
| EP-3034545-A1 | A process for the preparation of a graft copolymer comprising a polyolefin main chain and one or a multiple polymer side chains and the products obtained therefrom | SABIC Global Technologies B.V. (NL) | 2016-06-22 | — | — | EP | claimed |
| US-12570771-B2 | Curing catalyst used for curing of polymer, production method for said curing catalyst, mositure-curable composition, and production method for cured product | NITTO KASEI CO., LTD. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4682204-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2026-01-21 | — | — | EP | disclosed |
| EP-4656672-A1 | METHOD FOR PRODUCING CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4174052-B1 | CURING CATALYST USED FOR CURING OF POLYMER, PRODUCTION METHOD FOR SAID CURING CATALYST, MOISTURE-CURABLE COMPOSITION, AND PRODUCTION METHOD FOR CURED PRODUCT | NITTO KASEI CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| EP-4596622-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4567075-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025111365-A1 | METHOD OF PREPARING A MOISTURE CURABLE RESIN COMPOSITION WITH A NON-TIN CATALYST | KANEKA AMERICAS HOLDING, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-12312464-B2 | Curing catalyst used for curing of polymer, moisture curable composition, and method for producing cured product | NITTO KASEI CO., LTD. (JP) | 2025-05-27 | — | — | US | disclosed |
| EP-2202247-A1 | SUPPORTED NON-METALLOCENE CATALYST AND ITS PREPARATION METHOD | Sinopec Yangzi Petrochemical Company Ltd. (CN) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202246-A1 | NON-METALLOCENE CATALYST SUPPORTED ON MAGNESIUM COMPOUND AND ITS PREPARATION METHOD | Sinopec Yangzi Petrochemical Company Ltd. (CN) | 2010-06-30 | — | — | EP | disclosed |
| US-20100143712-A1 | SILANE-CROSSLINKING ADHESIVE OR SEALANT COMPRISING N-SILYLALKYLAMIDES AND USE THEREOF | HENKEL AG & CO. KGAA (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100081757-A1 | COMPOSITIONS CONSISTING OF PARTIALLY SILYL-TERMINATED POLYMERS | HENKEL AG & CO. KGAA (DE) | 2010-04-01 | — | — | US | disclosed |
| EP-1101484-B1 | Dental fillers | SHOFU KK (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-6620861-B1 | Fine particles covered with polysiloxane | KABUSHIKI KAISHA SHOFU (JP) | 2003-09-16 | — | — | US | disclosed |
| EP-1101484-A2 | Dental fillers | KABUSHIKI KAISHA SHOFU (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-4020010-A | TRANSESTERIFICATION CATALYSTSCOMPLEXING WITH STANNOUS CARBOXYLATE | BASF WYANDOTTE CORPORATION (US) | 1977-04-26 | — | — | US | disclosed |
| US-4018708-A | TRANSESTERIFICATION CATALYSTS | BASF WYANDOTTE CORPORATION (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570771-B2 | Curing catalyst used for curing of polymer, production method for said curing catalyst, mositure-curable composition, and production method for cured product | RPS6KB1, RPS6KA1, RPS6KB2 | ADRB2 1818/4885ADRB1 1801/4885ADRB3 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.